Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26

BIO-RAD LABORATORIES, INC.

2025-Q3 EPS reported $1.46 revenue$1,890,000,000

Revenue $653.0M, up slightly from $649.7M year-over-year.
GAAP net loss $341.9M ($12.70 loss per diluted share) vs net income $653.2M in Q3 2024.
Non-GAAP net income $60.8M ($2.26 per share) vs $56.3M ($2.02) in prior year.
GAAP gross margin declined to 52.6% from 54.8%; non-GAAP gross margin declined to 53.5% from 55.6%.
CEO cited disciplined cost management for better-than-expected operating margin despite funding headwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.